News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

News|Videos|March 5, 2025

Microwave Treatment: Advantages Over Traditional Approaches

Author(s)Sponsored by Swift

In this episode, Dustin Portela, DO, explores how Swift microwave therapy is transforming wart treatment, the science behind this technology, and how it reduces wart-related pain.

Episodes in this series

EP. 1 Introduction of Swift Microwave Therapy for Wart Treatment

EP. 1 Introduction of Swift Microwave Therapy for Wart Treatment

EP. 2 Traditional vs Microwave Wart Therapies: Insights from Swift’s Efficacy Data

EP. 2 Traditional vs Microwave Wart Therapies: Insights from Swift’s Efficacy Data

EP. 3 Microwave Treatment: Advantages Over Traditional Approaches

EP. 3 Microwave Treatment: Advantages Over Traditional Approaches

EP. 4 Patient Selection and Billing Considerations for Swift Wart Treatment

EP. 4 Patient Selection and Billing Considerations for Swift Wart Treatment

EP. 5 Practicing With Swift: Impacts and Opportunities Created

EP. 5 Practicing With Swift: Impacts and Opportunities Created

EP. 6 Operational Benefits With Swift As a Delegable Procedure

EP. 6 Operational Benefits With Swift As a Delegable Procedure

EP. 7 Key Takeaways for Adding Swift Wart Treatment to Your Practice

EP. 7 Key Takeaways for Adding Swift Wart Treatment to Your Practice

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Clinical Pearls for Management of Pediatric Atopic Dermatitis With Topicals

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Therapy Gaps in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Counseling Caregivers in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Escalating to Systemic Therapies in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Treatment Adherence in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 7th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC

First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

Phase 2 Nemolizumab Trial Opens for CPUO

Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1

© 2025 MJH Life Sciences^®

All rights reserved.